Latest news with #Varipulse
Yahoo
25-06-2025
- Business
- Yahoo
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio. On June 18, Oppenheimer reaffirmed its $140 price target and Outperform rating on Abbott Laboratories (NYSE:ABT), noting growing confidence in the company's Volt system and future glucose-ketone monitoring technology. Following the observation of live PFA (pulsed field ablation) case viewings of rival systems, such as Varipulse/CARTO and Farapulse/Opal, the research firm voiced increasing optimism concerning Volt. Varipulse's uptake has been 'subdued' despite price parity with Farapulse, according to Oppenheimer. Oppenheimer found two significant catalysts for Abbott Laboratories (NYSE:ABT) that might boost the company's performance in the second half of 2025. First, if Abbott leverages cost as a competitive advantage, the possible approval of Volt PMA might result in 'significant gains' in electrophysiology. The second driver is Abbott's glucose-ketone dual sensor system, which was recently revealed to be integrated with the insulin pump from Tandem Diabetes Care. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
25-06-2025
- Business
- Yahoo
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio. On June 18, Oppenheimer reaffirmed its $140 price target and Outperform rating on Abbott Laboratories (NYSE:ABT), noting growing confidence in the company's Volt system and future glucose-ketone monitoring technology. Following the observation of live PFA (pulsed field ablation) case viewings of rival systems, such as Varipulse/CARTO and Farapulse/Opal, the research firm voiced increasing optimism concerning Volt. Varipulse's uptake has been 'subdued' despite price parity with Farapulse, according to Oppenheimer. Oppenheimer found two significant catalysts for Abbott Laboratories (NYSE:ABT) that might boost the company's performance in the second half of 2025. First, if Abbott leverages cost as a competitive advantage, the possible approval of Volt PMA might result in 'significant gains' in electrophysiology. The second driver is Abbott's glucose-ketone dual sensor system, which was recently revealed to be integrated with the insulin pump from Tandem Diabetes Care. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
J&J's electrophysiology sales dip amid slow Varipulse start
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Johnson & Johnson failed to capitalize on the pulsed field ablation wave in the first quarter of 2025, despite recently launching its Varipulse device in the U.S. The healthcare giant on Tuesday reported strong growth for its cardiovascular portfolio — largely due to its recent M&A spree in the space — but electrophysiology sales fell year over year by nearly 2%. Electrophysiology was the only cardiovascular group to decline in the quarter, as sales for the segment overall grew by more than 16% to $2.1 billion. The decline, which J&J attributed to competition, contrasts with rivals' early reports: Medtronic touted strong adoption of its PFA device early in its launch, and Boston Scientific's electrophysiology sales skyrocketed by 138% last year to nearly $2 billion, posting triple-digit growth as early as the second quarter. PFA systems use non-thermal energy to affect heart tissue that causes atrial fibrillation, or an irregular heartbeat. Devices have only been on the market for a short time, but they are already eating up cryoablation and radiofrequency ablation procedures. Truist Securities analysts, in a Tuesday note, wrote that J&J missed Wall Street's sales estimates for electrophysiology by about $50 million, with a miss of about $9 million in the U.S. They added that J&J's struggles are likely to benefit Boston Scientific and Medtronic given their 'sustained head starts in PFA.' J&J received FDA approval for its Varipulse PFA device in November, trailing Boston Scientific and Medtronic to the market by almost one year. The company paused U.S. cases of Varipulse in January for roughly five weeks and worked with the FDA due to safety concerns. At the time of the pause, Wall Street analysts cautioned that it could discourage physicians from using the device, because rival systems had not been connected to patient safety issues. In February, RBC Capital Markets analysts said that physicians' enthusiasm for Varipulse may have been affected by the company's decision to stop U.S. cases, writing that J&J would have 'to take meaningful steps to educate healthcare professionals.' They wrote that the company should still 'be able to drive Varipulse adoption.' J.P. Morgan analysts, in a note after Tuesday's earnings call, echoed the concerns RBC discussed a few months ago. 'While [U.S.] Varipulse cases resumed in the quarter, we continue to expect the [O.U.S. and U.S.] challenges that Varipulse has had to potentially have a lasting negative impact on physician perception of the safety of the catheter,' the analysts wrote, 'especially in light of the several safe alternatives now on the market.' Despite the early success of Medtronic and Boston Scientific, the J.P. Morgan analysts wrote that J&J's electrophysiology weakness in the quarter was expected. Overall, medtech brought in sales of $8.02 billion, representing a 2.5% increase year over year. Recommended Reading J&J expects tariff charge of $400M this year
Yahoo
17-02-2025
- Health
- Yahoo
Johnson & Johnson to resume market release of Varipulse catheter in US
Johnson & Johnson is set to resume the limited market release of the Varipulse Catheter, a treatment option for atrial fibrillation (AFib), in the US. The temporary suspension of the device's US rollout began on 5 January 2025, following reports of four stroke events. This suspension affected the US External Evaluation and all Varipulse cases in the country. However, the latest decision to resume the market release follows a comprehensive investigation that confirmed the device's function as intended. The investigation, which looked into device, procedure, and patient-related factors, concluded that there is no difference in the performance of the Varipulse system configurations available worldwide. However, it was found that the risk of neurovascular events may increase with a high number of ablations, stacking of ablations, or ablations performed outside of the pulmonary veins. In a press statement, Johnson & Johnson said: 'We will continue to educate healthcare professionals with guidance around recommended practices aligned to our clinical studies.' The device will be available in all markets where it is launched commercially. The company also plans to update Varipulse's instructions for use to provide enhanced guidance. Healthcare providers are required to examine and comply with the revised IFU and share this information with patients. The system, which integrates pulsed field ablation (PFA) therapy with advanced mapping capabilities, is designed to deliver precise ablations to increase safety. The catheter's full integration is expected to minimise the need for multiple visualisation methods used in a single procedure, thereby creating a streamlined workflow. In November 2024, it received approval from the US Food and Drug Administration for the treatment of drug-refractory paroxysmal AFib. "Johnson & Johnson to resume market release of Varipulse catheter in US" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Reuters
15-02-2025
- Business
- Reuters
J&J resumes US rollout of Varipulse heart device after investigation
Feb 14 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Friday it has resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended. In January, the company had paused the heart device, a pulsed field ablation system, citing an abundance of caution as it investigated four reported stroke events. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
